Since the emergence of meticillin-resistant Staphylococcus aureus (MRSA), vancomycin has been the only uniformly effective treatment for staphylococcal infections in India, teicoplanin and linezolid not being commonly used. The incidence of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) has been increasing in various parts of the world. The first clinical isolate of VRSA was reported from the United States in 2002 (CDC, 2002) . More recently, some workers have reported vancomycin-resistant staphylococcal strains from Brazil (Palazzo et al., 2005) , Jordan (Bataineh, 2006) and India (Tiwari & Sen, 2006) . Vancomycin intermediateresistant Staphylococcus haemolyticus has been reported previously (Schwalbe et al., 1987) , and perhaps this is a critical antecedent of VISA. As documented reports of VISA/VRSA in India are very few (Assadullah et al., 2003) , we decided to monitor the vancomycin susceptibility of clinical meticillin-resistant Staphylococcus spp. in the tertiary care teaching hospital, JIPMER.
A total of 261 staphylococcal isolates consisting of 141 S. aureus isolates and 120 coagulase-negative staphylococci (CNS) were included. The clinical specimens included wound swabs, catheters, pus, urine, sputum and blood from inpatients and outpatients of the tertiary care teaching hospital, JIPMER. Staphylococci were identified according to standard methodology (Koneman et al., 2006) . The identity of the isolates was confirmed by a latex agglutination test, the HiStaph Latex test, performed according to the protocols supplied by the manufacturer (HiMedia). Staphylococci were obtained either as pure culture or as part of a polymicrobial infection. All S. aureus isolates and 30 CNS were subjected to susceptibility testing by the Kirby-Bauer disc diffusion method, the Brain Heart Infusion vancomycin screen agar test (6 mg vancomycin ml 21 )
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